Actively Recruiting
Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL
Led by Navy General Hospital, Beijing · Updated on 2020-09-09
100
Participants Needed
1
Research Sites
1056 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high effective in elderly patients with primary central nervous system lymphoma (PCNSL).
CONDITIONS
Official Title
Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Newly diagnosed histologically proven non-Hodgkin's lymphoma (NHL).
You will not qualify if you...
- Lymphoma involvement outside the brain, meninges, cerebrospinal fluid, or eyes.
- Age less than 18 years or greater than 75 years.
- Low bone marrow function with neutrophils below 1.5 x 10^9/L, platelets below 100 x 10^9/L, or hemoglobin less than 8 g/dL.
- Known immunosuppression such as HIV type I infection.
- History of any previous cancer.
- Kidney function with creatinine clearance below 60 mL/min.
- Heart failure classified as NYHA IIIB or IV.
- Uncontrolled infections.
- Active lung or liver disease that is not compensated.
- Prior treatment for primary central nervous system lymphoma except corticosteroids.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Navy General Hospital
Beijing, Beijing Municipality, China, 100048
Actively Recruiting
Research Team
L
Liren Qian, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here